Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein

Vaccine

Volumn 18, Issue 22, 2000, Pages 2426-2434

  Raviprakash, K ^a,b   Kochel, T J ^a   Ewing, D ^a   Simmons, M ^a   Phillips, I ^a   Hayes, C G ^a   Porter, K R ^a  

^a Virology Program   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Antibody response; Dengue virus; DNA vaccine; Mouse

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; GENE CONSTRUCT; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; RECOMBINANT PLASMID;

EID: 0034101295     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00570-8     Document Type: Article

References (46)

1. Chambers T.J., Hahn C.S., Galler R., Rice C.M. Flavivirus genome organization, expression and replication. Ann. Rev. Microbiol. 44:1990;649-688.
2. Halstead S.B. Pathogenesis of dengue: Challenges to molecular biology. Science. 239:1988;476-481.
3. Gubler D.J., Trent D.W. Emergence of epidemic dengue/dengue hemorrhagic fever as a public health problem in the Americas. Infect. Agents Dis. 2:1994;383-393.
4. Sabin A.B. Research on dengue fever during World War II. Am. J. Trop. Med. Hyg. 1:1952;30-50.
5. Halstead S.B. Etiologies of the experimental dengues of Siler and Simmons. Am. J. Trop. Med. Hyg. 23:1974;974-982.
6. Barrett A.D. Yellow fever vaccines. Biologicals. 25:1997;17-25.
7. Barrett A.D. Japanese encephalitis and dengue vaccines. Biologicals. 25:1997;27-34.
8. Chambers T.J., Tsai T.F., Pervikov Y., Monath T.P. Vaccine development against dengue and Japanese encephalitis: report of a WHO meeting. Vaccine. 15:1997;1491-1502.
9. Burke D.S., Nisalak A., Johnson D.E., Scot R.M. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38:1988;172-180.
10. Sangkawibha N., Rojansuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., Phantumachinda B., Halstead S.B. Risk factors in DSS: A prospective epidemiologic study in Rayong, Thailand. Am. J. Epidemiol. 120:1984;653-669.
11. Thein S., Aung M.M., Shwe T.N., Aye M., Zaw A., Aye K., Aye K.M., Aaskov J. Risk factors in dengue shock syndrome. Am. J. Trop. Med. Hyg. 56:1997;566-572.
12. Halstead S.B., O'Rourke E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146:(1):1997;201-217.
13. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., Burke D.S. Antibody dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:1989;444-451.
14. Rhodes G., Dwark V., Abai A. Injection of expression vectors containing viral genes induces cellular, humoral protective immunity. Vaccine. 93:1993;137-141.
15. Phillpotts R.J., Venugopal K., Brooks T. Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. Arch. Virol. 141:1996;743-749.
16. Schmaljohn C., Vanderzanden L., Bray M., Custer D., Meyer B., Li D., Rossi C., Fuller D., Fuller J., Haynes J., Huggins J. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and central European encephalitis virus protect mice from homologous and heterologous challenge. J. Virol. 71:1997;9563-9569.
17. Lin Y.L., Chen L.K., Liao C.L., Yeh C.T., Ma S.H., Chen J.L., Huang Y.L., Chen S.S., Chiang H.Y. DNA immunization with Japanese encephalitis virus non-structural protein NS1 elicits protective immunity in mice. J. Virol. 72:1998;191-200.
18. Konishi E., Yamaoka M., Win K.-S., Kurane I., Mason P.W. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol. 72:1998;4925-4930.
19. Colombage G., Hall R., Pavy M., Lobigs M. DNA-based and alphavirus-vectored immunization with prM and E proteins elicits long lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology. 250:1998;151-163.
20. Kochel T., Wu S.-J., Raviprakash K., Hobart P., Hoffman S., Porter K., Hayes C. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine. 15:1997;547-552.
21. Porter K.R., Kochel T.J., Wu S.-J., Raviprakash K., Phillips I., Hayes C.G. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody response. Arch. Virol. 143:1998;997-1003.
22. Sambrook J., Fritsch E., Maniatis T. Molecular cloning: A laboratory manual. 1989;CSHL Press, New York.
23. Laemmli U.K. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature. 227:1970;680.
24. Ansari M., Shope R., Malik S. Evaluation of vero cell lysate antigen for the ELISA of flavivirus. J. Clin. Lab. Anal. 7:1993;230-237.
25. Russel P.K., Nisalak A., Sukhavachana P., Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J. Immun. 99:1967;285-290.
26. Allison S.L., Stadler K., Mandl C.W., Kunz C., Heinz F.X. Synthesis and secretion of recombinant tick borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69:1995;5816-5820.
27. Fonseca B.A.L., Pincus S., Shope R.F., Paoletti E., Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine. 12:1994;279-285.
28. Konishi E., Pincus S., Paoletti E., Shope R.E., Burrage T., Mason P.W. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology. 188:1992;714-720.
29. Mason P.W., Pincus S., Fournier M.J., Mason T.L., Shope R.E., Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology. 180:1991;294-305.
30. Henchal E.A., McCown J.M., Burke D.S., Seguin M.C., Brandt W.E. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 34:1985;162-169.
31. Trirawatanapong T., Chandran B., Putnak R., Padmanabhan R. Mapping of a region of dengue virus type 2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene. 16:1992;139-150.
32. Lin B., Parrish C.R., Murray J.M., Wright P.J. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology. 202:1994;885-890.
33. Kliks S.C., Nimmanitya S., Nisalak A., Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:1988;411-419.
34. Kaufman B.M., Summers P.L., Dubois D.R., Eckels K.H. Monoclonal antibodies against dengue 2 virus E glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:1987;427-434.
35. Guirakhoo F., Bolin R.A., Roehrig J.T. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology. 191:1992;921-931.
36. Konishi E., Mason P.W. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J. Virol. 67:1993;1672-1675.
37. Heinz F.X., Stiasny K., Puschner-Auer G., Holzman H., Allison S.L., Mandl C.W., Kunz C. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology. 198:1994;109-117.
38. Men R., Bray M., Lai C.-J. Carboxy terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J. Virol. 65:1991;1400-1407.
39. Jan L.-R., Yang C.-S., Henchal L.S., Sumiyoshi H., Summers P.L., Dubois D.R., Lai C.-J. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxy terminal truncation of Japanese encephalitis virus envelope glycoprotein. Am. J. Trop. Med. Hyg. 48:1993;412-423.
40. Heinz F.X., Kunz C. Concentration and purification of tick-borne encephalitis virus grown in suspensions of chick embryo cells. Acta Virol. 21:1997;301-307.
41. Russell P.K., Brandt W.E., Dalrymple J.M. Chemical and antigenic structure of flaviviruses. Schlesinger R.W. The Togaviruses. 1980;503-529 Academic Press, New York.
42. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. 375:1995;291-298.
43. Heinz F.X., Allison S.L., Stiasny K., Schalich J., Holzman H., Mandl C.W., Kunz C. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine. 13:1995;1636-1642.
44. Cole G.A., Wisseman C.L. Jr. Pathogenesis of type 1 dengue virus infection in suckling, weanling and adult mice. Am. J. Epidemiol. 89:1969;669-680.
45. Mason P.W., McAda P.C., Mason T.L., Fournier M.J. Sequence of the dengue-1 virus genome in the region encoding the three structural proeins and major non-structural protein NS1. Virology. 161:1987;262-267.
46. Puri B., Nelson W.M., Henchal E.A., Hoke C.H., Eckels K.H., Dubois D.R., Porter K.R., Hayes C.G. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J. Gen. Virol. 78:1997;2287-2291.